Helle Pappot

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi [Lung cancer--a technological challenge II. New approaches to treatment]
    Helle Pappot
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:4243-5. 2004
  2. ncbi The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis
    Helle Pappot
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Lung Cancer 51:193-200. 2006
  3. pmc uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications
    Line Hammer Dohn
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    PLoS ONE 10:e0135824. 2015
  4. ncbi [Lung cancer--a technological challenge I. Diagnostics and staging]
    Trine Jakobi Nøttrup
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:4241-3. 2004
  5. doi Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder
    Line Hammer Dohn
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark Electronic address
    Urol Oncol 33:165.e15-24. 2015
  6. doi The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer
    Charlotte E Almasi
    The Finsen Laboratory, Rigshospitalet Biotech Research and Innovation Centre BRIC, University of Copenhagen, DK 2200 Copenhagen, Denmark
    APMIS 121:189-96. 2013
  7. doi Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer
    Charlotte Elberling Almasi
    Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloesvej 5, Copenhagen N, Denmark
    APMIS 117:755-61. 2009
  8. ncbi Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer
    Line V Hansen
    The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark
    Lung Cancer 58:260-6. 2007
  9. ncbi Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
    Charlotte Elberling Almasi
    The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK 2100, Denmark
    Lung Cancer 48:349-55. 2005
  10. ncbi Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival
    Birgit Guldhammer Skov
    Department of Pathology, Herlev Hospital, Division Gentofte, Niels Andersens Vej 65, 2900 Copenhagen, Hellerup, Denmark
    Lung Cancer 59:88-94. 2008

Collaborators

  • Barbara M Fischer
  • Ib Jarle Christensen
  • Halla Skuladottir
  • Gunilla Høyer-Hansen
  • Line Hammer Dohn
  • Charlotte Elberling Almasi
  • Hans von der Maase
  • Martin Illemann
  • Charlotte E Almasi
  • Birgit Guldhammer Skov
  • Line V Hansen
  • Trine Jakobi Nøttrup
  • Jens Hostmark
  • Ole Didrik Laerum
  • Peter Thind
  • Jorunn Litlekalsoy
  • Lisbeth Salling
  • Benedikte Richter Iversen
  • Ole D Laerum
  • Lars Drivsholm
  • Michael Ploug
  • Birgit G Skov
  • Keld Danø

Detail Information

Publications11

  1. ncbi [Lung cancer--a technological challenge II. New approaches to treatment]
    Helle Pappot
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:4243-5. 2004
  2. ncbi The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis
    Helle Pappot
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Lung Cancer 51:193-200. 2006
    ..To understand these interactions and the clinical importance of the tissue levels of uPA, PAI-1 and uPA-PAI-1 complex, the results suggest further exploratory studies of the components in pulmonary adenocarcinomas and other cancers...
  3. pmc uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications
    Line Hammer Dohn
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    PLoS ONE 10:e0135824. 2015
    ..Our investigations have generated new and valuable biological information about the cell types being involved in tumour invasion and progression through the plasminogen activation system. ..
  4. ncbi [Lung cancer--a technological challenge I. Diagnostics and staging]
    Trine Jakobi Nøttrup
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:4241-3. 2004
  5. doi Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder
    Line Hammer Dohn
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark Electronic address
    Urol Oncol 33:165.e15-24. 2015
    ..The expression and localization of uPAR and its prognostic significance is only limitedly investigated in urothelial bladder neoplasia...
  6. doi The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer
    Charlotte E Almasi
    The Finsen Laboratory, Rigshospitalet Biotech Research and Innovation Centre BRIC, University of Copenhagen, DK 2200 Copenhagen, Denmark
    APMIS 121:189-96. 2013
    ..9 (95% confidence interval (CI): 1.1-3.3), compared to patients with levels below the first tertile. High serum uPAR(I) levels are associated with short OS in SCLC patient, independent of LDH and PS...
  7. doi Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer
    Charlotte Elberling Almasi
    Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloesvej 5, Copenhagen N, Denmark
    APMIS 117:755-61. 2009
    ..3, 2.8 and 3.8 respectively). High blood levels of intact uPAR and its cleaved forms are associated with poor prognosis in NSCLC...
  8. ncbi Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer
    Line V Hansen
    The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark
    Lung Cancer 58:260-6. 2007
    ..4A expression. In the present study, we therefore explored the possible association between C4.4A expression and prognosis in patients with non-small cell lung cancer (NSCLC)...
  9. ncbi Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
    Charlotte Elberling Almasi
    The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK 2100, Denmark
    Lung Cancer 48:349-55. 2005
    ..The purpose of this study was to determine the prognostic impact of liberated domain I of the urokinase plasminogen activator receptor, uPAR(I), in tumour extracts from patients resected for the squamous cell carcinoma (SCC) of the lung...
  10. ncbi Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival
    Birgit Guldhammer Skov
    Department of Pathology, Herlev Hospital, Division Gentofte, Niels Andersens Vej 65, 2900 Copenhagen, Hellerup, Denmark
    Lung Cancer 59:88-94. 2008
    ..We examined the expression of ERalpha, ERbeta and progesterone in a well defined cohort of patients with NSCLC with more than 15 years of follow up, and related the results to gender and survival...
  11. ncbi [Women and lung cancer--epidemiology, smoking and biology]
    Barbara Malene Fischer
    H S Rigshospitalet, Finsen Centret, Onkologisk Klinik København ø
    Ugeskr Laeger 165:4550-2. 2003